12/04/2024 6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
11/14/2024 2:10 PM | Cormorant Asset Management, LP (Filed by) EyePoint Pharmaceuticals (Subject)
| Form SC 13G/A | |
11/12/2024 1:31 PM | EyePoint Pharmaceuticals (Subject) VANGUARD GROUP INC (Filed by)
| Form SC 13G/A | |
11/12/2024 8:33 AM | Adage Capital Management, L.P. (Filed by) EyePoint Pharmaceuticals (Subject)
| Form SC 13G/A | |
11/07/2024 6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
11/06/2024 7:54 AM | EyePoint Pharmaceuticals (Subject) FEDERATED HERMES, INC. (Filed by) FEDERATED HERMES, INC. (Filed by)
| Form SC 13G | |
11/04/2024 10:57 AM | EyePoint Pharmaceuticals (Subject) VANGUARD GROUP INC (Filed by)
| Form SC 13G/A | |
|
10/31/2024 3:16 PM | EyePoint Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
10/31/2024 11:51 AM | EyePoint Pharmaceuticals (Subject) FRANKLIN RESOURCES INC (Filed by)
| Form SCHEDULE 13G/A | |
10/30/2024 3:20 PM | EyePoint Pharmaceuticals (Filer)
| Form 424B5 | |
10/28/2024 4:17 PM | EyePoint Pharmaceuticals (Filer)
| Form 424B5 | |
10/28/2024 6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
10/24/2024 6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
10/23/2024 3:34 PM | ADAMIS ANTHONY P (Reporting) EyePoint Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
10/22/2024 2:24 PM | BlackRock, Inc. (Filed by) EyePoint Pharmaceuticals (Subject)
| Form SC 13G | |
10/15/2024 10:58 AM | EyePoint Pharmaceuticals (Subject) GUYER DAVID R (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
09/05/2024 3:02 PM | EyePoint Pharmaceuticals (Issuer) Hassan Fred (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/05/2024 3:02 PM | EyePoint Pharmaceuticals (Issuer) Hassan Fred (Reporting)
| Form 3 Initial statement of beneficial ownership of securities | |
09/04/2024 6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/21/2024 3:32 PM | DICICCO WENDY F (Reporting) EyePoint Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/18/2024 11:15 PM | EyePoint Pharmaceuticals (Filer)
| Form EFFECT | |
08/08/2024 3:42 PM | EyePoint Pharmaceuticals (Filer)
| Form S-3 Registration statement under Securities Act of 1933 | |
08/08/2024 3:46 PM | EyePoint Pharmaceuticals (Filer)
| Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
08/07/2024 6:00 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
07/26/2024 3:47 PM | EyePoint Pharmaceuticals (Issuer) Lurker Nancy (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/16/2024 3:24 PM | EyePoint Pharmaceuticals (Issuer) GUYER DAVID R (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/12/2024 4:00 PM | EyePoint Pharmaceuticals (Issuer) Zaderej Karen L. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/12/2024 4:03 PM | EyePoint Pharmaceuticals (Issuer) Lurker Nancy (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/12/2024 4:04 PM | Duker Jay S. (Reporting) EyePoint Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/26/2024 8:25 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
06/25/2024 3:16 PM | ADAMIS ANTHONY P (Reporting) EyePoint Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/21/2024 6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
06/04/2024 3:28 PM | EyePoint Pharmaceuticals (Issuer) GUYER DAVID R (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/28/2024 3:22 PM | Elston George (Reporting) EyePoint Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/28/2024 6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/16/2024 4:19 PM | EyePoint Pharmaceuticals (Issuer) GUYER DAVID R (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/14/2024 3:39 PM | EyePoint Pharmaceuticals (Subject) GUYER DAVID R (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
05/09/2024 9:12 AM | EyePoint Pharmaceuticals (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
05/08/2024 3:23 PM | Chen Bihua (Reporting) Cormorant Asset Management, LP (Reporting) Cormorant Global Healthcare Master Fund, LP (Reporting) EyePoint Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/08/2024 6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/06/2024 8:25 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
Vacuum up cash with these special trades? (Ad) Have you ever heard about a “volatility vacuum?”
Most people haven’t.
It all revolves around this formula right here.
Now, the most important thing is that this equation — when applied to certain tickers at a certain time each month —- can trigger these “volatility vacuums.”
And when that happens, anyone has the shot at sucking out payouts of $290, $350, even $1,350 in as little as 24 hours.
(With just a $1k starting stake!)
Granted, there were smaller wins and those that did not work out but best of all, we can know exactly when these opportunities will hit.
I’ve used this info to create a Cash Calendar that lays out the precise dates of these payouts.
And I’m sending it for FREE to anyone who joins me during my FREE training right here. |
05/01/2024 4:08 PM | Adage Capital Management, L.P. (Filed by) EyePoint Pharmaceuticals (Subject)
| Form SC 13G/A | |
04/30/2024 7:53 PM | Adage Capital Management, L.P. (Filed by) EyePoint Pharmaceuticals (Subject)
| Form SC 13G | |
04/22/2024 3:15 PM | Adage Capital Management, L.P. (Reporting) Atchinson Robert (Reporting) EyePoint Pharmaceuticals (Issuer) Gross Phillip (Reporting)
| Form 3 Initial statement of beneficial ownership of securities | |
04/02/2024 4:27 PM | EyePoint Pharmaceuticals (Issuer) Paggiarino Dario A. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/08/2024 12:53 PM | EyePoint Pharmaceuticals (Filer)
| Form 10-K Annual report pursuant to Section 13 or 15(d) | |
03/07/2024 6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
03/04/2024 4:37 PM | EyePoint Pharmaceuticals (Issuer) Ribeiro Ramiro (Reporting)
| Form 3 Initial statement of beneficial ownership of securities | |
03/04/2024 4:40 PM | EyePoint Pharmaceuticals (Issuer) Ribeiro Ramiro (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/04/2024 6:01 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
02/14/2024 8:08 PM | EyePoint Pharmaceuticals (Subject) RA CAPITAL MANAGEMENT, L.P. (Filed by)
| Form SC 13G/A | |
02/13/2024 4:37 PM | Duker Jay S. (Reporting) EyePoint Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/13/2024 4:38 PM | Elston George (Reporting) EyePoint Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/13/2024 4:38 PM | EyePoint Pharmaceuticals (Issuer) Jones David Scott (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/13/2024 4:39 PM | EyePoint Pharmaceuticals (Issuer) Paggiarino Dario A. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/13/2024 4:40 PM | EyePoint Pharmaceuticals (Issuer) Lurker Nancy (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/13/2024 11:00 AM | EyePoint Pharmaceuticals (Subject) SUVRETTA CAPITAL MANAGEMENT, LLC (Filed by)
| Form SC 13G/A | |
02/07/2024 6:54 AM | ADAGE CAPITAL PARTNERS GP, L.L.C. (Filed by) EyePoint Pharmaceuticals (Subject)
| Form SC 13G/A | |
02/06/2024 9:55 AM | EyePoint Pharmaceuticals (Subject) FRANKLIN RESOURCES INC (Filed by)
| Form SC 13G/A | |
02/05/2024 4:15 PM | EyePoint Pharmaceuticals (Issuer) Jones David Scott (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/02/2024 3:22 PM | EyePoint Pharmaceuticals (Subject) Jones David Scott (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
01/30/2024 3:53 PM | EyePoint Pharmaceuticals (Issuer) Paggiarino Dario A. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/29/2024 4:51 PM | EyePoint Pharmaceuticals (Issuer) Paggiarino Dario A. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/29/2024 4:54 PM | EyePoint Pharmaceuticals (Issuer) Jones David Scott (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/25/2024 5:24 PM | EyePoint Pharmaceuticals (Issuer) Lurker Nancy (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/25/2024 5:26 PM | EyePoint Pharmaceuticals (Issuer) Paggiarino Dario A. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/24/2024 3:50 PM | EyePoint Pharmaceuticals (Issuer) Jones David Scott (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/24/2024 3:25 PM | EyePoint Pharmaceuticals (Subject) Lurker Nancy (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
01/23/2024 3:42 PM | EyePoint Pharmaceuticals (Subject) Lurker Nancy (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
01/23/2024 3:19 PM | EyePoint Pharmaceuticals (Subject) Paggiarino Dario A. (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
01/22/2024 3:19 PM | EyePoint Pharmaceuticals (Subject) Jones David Scott (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
01/16/2024 5:55 PM | EyePoint Pharmaceuticals (Issuer) Ocumension Therapeutics (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/16/2024 5:01 PM | EyePoint Pharmaceuticals (Issuer) Liu Ye (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/11/2024 4:33 PM | EyePoint Pharmaceuticals (Subject) Ocumension Therapeutics (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
01/10/2024 3:53 PM | EyePoint Pharmaceuticals (Issuer) Paggiarino Dario A. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/10/2024 6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
01/09/2024 8:28 PM | EyePoint Pharmaceuticals (Issuer) Paggiarino Dario A. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/09/2024 8:17 PM | EyePoint Pharmaceuticals (Issuer) Lurker Nancy (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/09/2024 7:53 PM | ADAMIS ANTHONY P (Reporting) EyePoint Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/09/2024 7:53 PM | ANDO GORAN (Reporting) EyePoint Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/09/2024 7:54 PM | DICICCO WENDY F (Reporting) EyePoint Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/09/2024 7:54 PM | Duty Stuart (Reporting) EyePoint Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/09/2024 7:55 PM | EyePoint Pharmaceuticals (Issuer) Landis John B. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/09/2024 7:56 PM | EyePoint Pharmaceuticals (Issuer) GUYER DAVID R (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/09/2024 8:04 PM | Elston George (Reporting) EyePoint Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/09/2024 8:07 PM | Duker Jay S. (Reporting) EyePoint Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/09/2024 8:09 PM | EyePoint Pharmaceuticals (Issuer) Jones David Scott (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/09/2024 8:11 PM | EyePoint Pharmaceuticals (Issuer) Pine Michael Craig (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/09/2024 8:12 PM | EyePoint Pharmaceuticals (Issuer) Zaderej Karen L. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/03/2024 5:37 PM | EyePoint Pharmaceuticals (Issuer) Lurker Nancy (Reporting)
| Form 4/A | |
01/02/2024 4:41 PM | EyePoint Pharmaceuticals (Issuer) Lurker Nancy (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
Is the Trump/Musk duo good for shares of TSLA? (Ad) If you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows…
But according to our one expert, new yearly highs are on the horizon…
In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker.
Which is why we’re emailing you now…
You see, most people will simply buy shares of Tesla ahead of the election…
But as they say “There is more than one way to skin a cat”
In fact, we’ve found another way to play shares of Tesla. Discover how to trade Tesla, simply follow this link here. |